000			03808nam a22006017a 4500
008			140821s20142014 xxu||||| |||| 00| 0 eng d
022			_a0344-5704
040			_aOvid MEDLINE(R)
099			_a24531558
245			_aPharmacokinetics of doxorubicin in pregnant women.
251			_aCancer Chemotherapy & Pharmacology. 73(4):789-97, 2014 Apr.
252			_aCancer Chemother Pharmacol. 73(4):789-97, 2014 Apr.
253			_aCancer chemotherapy and pharmacology
260			_c2014
260			_fFY2014
266			_d2014-08-21
520			_aCONCLUSIONS: In pregnant subjects, we observed significantly lower doxorubicin CL in our 72 h and most of our 48 h sampling comparisons with previously reported non-pregnant subjects. However, the parameters were within the range previously reported in smaller studies. At this time, we cannot recommend alternate dosage strategies for pregnant women. Further research is needed to understand the mechanism of doxorubicin pharmacokinetic 140821s during pregnancy and optimize care for pregnant women.
520			_aMETHODS: During mid- to late-pregnancy, serial blood and urine samples were collected over 72 h from seven women treated with doxorubicin for malignancies. PK parameters were estimated using non-compartmental techniques. Pregnancy parameters were compared to those previously reported non-pregnant subjects.
520			_aPURPOSE: Our objective was to evaluate the pharmacokinetics (PK) of doxorubicin during pregnancy compared to previously published data from non-pregnant subjects.
520			_aRESULTS: During pregnancy, mean (+SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 + 80 mL/min/m(2); steady-state volume of distribution (Vss), 1,132 + 476 L/m(2); and terminal half-life (T1/2), 40.3 + 8.9 h. The BSA-adjusted CL was significantly decreased (p < 0.01) and T1/2 was not different compared to non-pregnant women. Truncating our data to 48 h, PK parameters were: CL, 499 + 116 ml/min/m(2); Vss, 843 + 391 L/m(2); and T1/2, 24.8 + 5.9 h. The BSA-adjusted CL in pregnancy compared to non-pregnant data was significantly decreased in 2 of 3 non-pregnant studies (p < 0.05, < 0.05, NS). Vss and T1/2 were not significantly different.
546			_aEnglish
650			_a*Antibiotics, Antineoplastic/pk [Pharmacokinetics]
650			_a*Doxorubicin/pk [Pharmacokinetics]
650			_a*Neoplasms/dt [Drug Therapy]
650			_a*Neoplasms/me [Metabolism]
650			_a*Pregnancy Complications, Neoplastic/dt [Drug Therapy]
650			_a*Pregnancy Complications, Neoplastic/me [Metabolism]
650			_aAdministration, Intravenous
650			_aAdult
650			_aAntibiotics, Antineoplastic/ad [Administration & Dosage]
650			_aAntibiotics, Antineoplastic/bl [Blood]
650			_aAntibiotics, Antineoplastic/ur [Urine]
650			_aDoxorubicin/ad [Administration & Dosage]
650			_aDoxorubicin/bl [Blood]
650			_aDoxorubicin/ur [Urine]
650			_aFemale
650			_aHumans
650			_aMiddle Aged
650			_aNeoplasms/bl [Blood]
650			_aNeoplasms/ur [Urine]
650			_aPregnancy
650			_aPregnancy Complications, Neoplastic/bl [Blood]
650			_aPregnancy Complications, Neoplastic/ur [Urine]
650			_aYoung Adult
651			_aMedStar Health Research Institute
657			_aJournal Article
657			_aResearch Support, N.I.H., Extramural
700			_aMiodovnik, Menachem
700			_aUmans, Jason G
790			_aAkbarzadeh A, Berg SL, Easterling TR, Eyal S, Feldman EM, Hays K, Hebert MF, Kaplan HG, Miodovnik M, Puhl K, Ryu RJ, Scorsone KA, Umans JG
856			_uhttp://dx.doi.org/10.1007/s00280-014-2406-z _zhttp://dx.doi.org/10.1007/s00280-014-2406-z
942			_cART _dArticle
999			_c1501 _d1501